Proceedings: Interaction of neuroleptic and cholinergic drugs with central dopaminergic mechanisms.
D000818:Animals; D001058:Apomorphine / Q000494:pharmacology; D003913:Dextroamphetamine / Q000494:pharmacology; D004298:Dopamine / Q000502:physiology*; D006801:Humans; D006892:Hydroxydopamines / Q000494:pharmacology; D008694:Methamphetamine / Q000037:antagonists & inhibitors / Q000494:pharmacology; D009043:Motor Activity / Q000187:drug effects; D010277:Parasympathomimetics / Q000494:pharmacology*; D051381:Rats; D013239:Stereotyped Behavior / Q000187:drug effects; D014149:Tranquilizing Agents / Q000494:pharmacology*
D006892:Hydroxydopamines; D010277:Parasympathomimetics; D014149:Tranquilizing Agents; D008694:Methamphetamine; D001058:Apomorphine; D003913:Dextroamphetamine; D004298:Dopamine